Heptares makes Daniel Grau president
This article was originally published in Scrip
GPCR drug discovery company Heptares Therapeutics has appointed Daniel Grau president. Mr Grau has been a senior advisor to Heptares since 2010, and will report to CEO Malcolm Weir. Mr Grau previously served as president and CEO of Cortria Corporation, and is currently a member of the product advisory board of Concert Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.